Description: Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. The Company is involved in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company's prescription drug candidate is CaPre, which is being developed for the treatment of severe hypertriglyceridemia and eventually mild to moderate hypertriglyceridemia. The Company's ONEMIA has a natural health product status in Canada, and it is commercialized as a medical food in the United States. Onemia is a purified omega-3 phospholipids concentrate derived from krill oil with lower levels of phospholipids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) content than CaPre.
Home Page: www.acastipharma.com
ACST Technical Analysis
3009 boulevard de la Concorde East
Laval,
QC
H7E 2B5
Canada
Phone:
450 687 2262
Officers
| Name | Title |
|---|---|
| Ms. Janelle D'Alvise | Pres, CEO, Corp. Sec. & Director |
| Dr. Pierre Lemieux M.D., Ph.D. | Co-Founder, COO & Chief Scientific Officer |
| Mr. Brian D. Ford CPA, CA | Chief Financial Officer |
| Dr. George Kottayil | Chief Operating Officer of US |
| Mr. Prashant Kohli | Chief Commercial Officer |
| Dr. Yves Lachance Ph.D. | VP of Quality & Compliance |
| Ms. Christine Pelletier | Sr. Director of HR |
Exchange: V
Country: CA : Canada
Currency: Canadian Dollar (C$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1605 |
| Price-to-Sales TTM: | 194.2993 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |